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Systemic fibrotic diseases such as systemic scle-
rosis (SSc) and organ-specific fibrosis such as kid-
ney fibrosis, idiopathic pulmonary fibrosis, and   
liver cirrhosis share common pathophysiological 
mechanisms  (Bataller  and  Brenner,  2005; Varga 
and Abraham, 2007; Strieter and Mehrad, 2009). 
Tissue fibrosis results from an increased release   
of extracellular matrix from aberrantly activated 
fibroblasts (Varga and Abraham, 2007; Gabrielli   
et  al.,  2009). The  accumulating  extracellular 
matrix disrupts the physiological tissue structure, 
leading to organ dysfunction and contributing to 
the  high  morbidity  and  increased  mortality  of   
affected patients (Chung et al., 2007; Steen and 
Medsger, 2007). However, the mechanisms for 
pathological fibroblast activation are incompletely 
understood. Consequently, therapeutic approaches 
selectively targeting the molecular activation of 
fibroblasts are not yet available for clinical use.
Tissue fibrosis is preceded by microvascular 
injury in SSc, leading to a progressive loss of 
capillaries (Gabrielli et al., 2009). The vascular 
damage with exposure of subendothelial con-
nective tissue results in ongoing activation of 
platelets. The levels of several platelet-derived 
molecules such as -thrombomodulin, platelet 
factor 4, and platelet-derived growth factor are 
elevated in SSc patients (Kahaleh et al., 1982; 
Postlethwaite and Chiang, 2007). In addition, 
elevated levels of circulating platelet aggregates 
have also been described (Kahaleh et al., 1982). 
Moreover, platelets from SSc patients express 
markers of activation such as increased expression 
of the 65-kD receptor for type I collagen and 
enhanced  activity  of  phosphatidylinositol-3   
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Vascular damage and platelet activation are associated with tissue remodeling in diseases 
such as systemic sclerosis, but the molecular mechanisms underlying this association have 
not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) 
stored in platelets strongly induces extracellular matrix synthesis in interstitial fibroblasts 
via activation of 5-HT2B receptors (5-HT2B) in a transforming growth factor  (TGF-)–
dependent manner. Dermal fibrosis was reduced in 5-HT2B
/ mice using both inducible and 
genetic models of fibrosis. Pharmacologic inactivation of 5-HT2B also effectively prevented 
the onset of experimental fibrosis and ameliorated established fibrosis. Moreover, inhibition 
of platelet activation prevented fibrosis in different models of skin fibrosis. Consistently, 
mice deficient for TPH1, the rate-limiting enzyme for 5-HT production outside the central 
nervous system, showed reduced experimental skin fibrosis. These findings suggest that  
5-HT/5-HT2B signaling links vascular damage and platelet activation to tissue remodeling 
and identify 5-HT2B as a novel therapeutic target to treat fibrotic diseases.
© 2011 Dees et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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5-HT did not enhance the stability of type I collagen or   
fibronectin-1 messenger RNA (mRNA; Fig. S1, A–C) but 
stimulated the release of collagen by increasing transcription 
in reporter assays (P = 0.05; Fig. S1 D).
The profibrotic effects of 5-HT are mediated by 5-HT2B
Consistent with a previous study, we observed that three dif-
ferent receptors for 5-HT are expressed in dermal fibroblasts: 
5-HT1B, 5-HT2A, and 5-HT2B (Slominski et al., 2003). In 
contrast to 5-HT1B and 5-HT2A, the mRNA levels of 5-HT2B 
were up-regulated by 143 ± 17% in SSc fibroblasts compared 
with healthy controls (P < 0.05; unpublished data). To investi-
gate which of these receptors mediates the profibrotic effects 
of 5-HT, dermal fibroblasts were incubated with selective   
serotonin receptor inhibitors. Inhibition of 5-HT1B by SB 
224289 did not reduce the stimulatory effects of 5-HT on 
extracellular matrix production in SSc fibroblasts (Fig. 2, A–D). 
In contrast, the 5-HT2 inhibitor terguride decreased mRNA 
levels of col 1a1, col 1a2, and fibronectin-1 and also the release 
of collagen protein in a dose-dependent manner (Fig. S2, A–D). 
Most pronounced effects were observed at a concentration of 
1.0 µM, with an almost complete blockade of 5-HT–induced 
extracellular matrix expression. To discriminate between   
5-HT2A and 5-HT2B, the 5-HT2A inhibitor ketanserin and 
the 5-HT2B antagonist SB 204741 were used. No inhibitory   
effects were observed with ketanserin up to 1 µM, whereas SB 
204741 at 1 µM completely prevented induction of extracel-
lular matrix synthesis by 5-HT in SSc fibroblasts (Fig. 2, A–D). 
No differences in metabolic activity, as measured by conver-
sion of microtiter tetrazolium (MTT), or in the number of   
kinase (Postlethwaite and Chiang, 2007). However, the role of 
platelet activation in the pathogenesis of SSc and other fi-
brotic diseases has not yet been established.
5-hydroxytryptamine (5-HT; serotonin) is another potent 
mediator, which is released upon activation of platelets and is 
elevated in the blood of SSc patients (Stachów et al., 1979; 
Biondi et al., 1988; Hervé et al., 1995). The rate-limiting step 
of 5-HT synthesis is catalyzed by TPHs (tryptophan hydroxy-
lases), whereof two isoforms have been described: TPH1 is 
mainly expressed in the periphery, whereas the expression of 
TPH2 is restricted to neuronal cells and the central nervous 
system (Walther et al., 2003a).
Based on (a) the activation of platelets upon microvascular 
injury, (b) the release of 5-HT during platelet activation, and 
(c) the potent biological effects of 5-HT, we hypothesized 
that 5-HT signaling might be involved in the pathogenesis of 
fibrosis. The cellular effects of 5-HT are mediated by seven 
families of 5-HT receptors, 5-HT1 to 5-HT7, some of which 
comprise several different members (Humphrey et al., 1993). 
Nonselective antagonists of 5-HT2 signaling such as tergu-
ride and cyproheptadine are already in current therapeutic 
use. A low rate of side effects has been observed in long-term 
follow-ups, suggesting that inhibition of 5-HT2 receptor sig-
naling is well tolerated in humans (von Werner et al., 1989; 
Moertel et al., 1991). In addition, selective inhibitors have 
been developed targeting individual members of the 5-HT2 
subfamily, including SB 204741, which inhibits 5-HT2B in 
pharmacologically  relevant  concentrations  (Bonhaus  et  al., 
1995; Glusa and Pertz, 2000). Using pharmacologic as well as 
genetic approaches and different experimental models of fi-
brosis, we demonstrate that 5-HT/5-HT2B signaling plays a 
central role in skin fibrosis. Together with the clinical avail-
ability of selective small molecular weight inhibitors, targeting 
5-HT2B signaling might be a promising strategy for the treat-
ment of fibrosis.
RESULTS
5-HT stimulates the production of extracellular matrix  
in SSc and healthy dermal fibroblasts
We first analyzed whether 5-HT stimulates the production of 
extracellular matrix. Therefore, fibroblasts from SSc patients 
and healthy subjects were stimulated with 5-HT at biologi-
cally relevant concentrations (Kasho et al., 1998; Wouters et al., 
2007). 5-HT dose-dependently induced the expression of ex-
tracellular matrix proteins with maximal induction at a con-
centration of 1 µM (Fig. 1, A–D). Higher concentrations of 
5-HT did not further increase the expression of extracellular 
matrix proteins but resulted in toxic effects (unpublished 
data). 5-HT increased the expression of col 1a1 by 211 ± 14% 
(P < 0.05; Fig. 1 A). In addition to col 1a1, 5-HT also induced 
the expression of col 1a2 and fibronectin-1 in a dose-dependent 
manner (Fig. 1, B and C). Similarly, the release of collagen pro-
tein from SSc fibroblasts was increased by up to 198 ± 53%   
(P < 0.05; Fig. 1 D). 5-HT also induced the expression of colla-
gen in dermal fibroblasts from healthy individuals without sig-
nificant differences to fibroblasts from SSc patients (Fig. 1, A–D). 
Figure 1.  5-HT stimulates the production of extracellular matrix  
in dermal fibroblasts. (A–C) mRNA levels of col 1a1 (A), col 1a2 (B), and  
fibronectin-1 (C) after stimulation of SSc and healthy dermal fibroblasts 
with 5-HT. (D) The release of collagen protein from dermal fibroblasts upon 
5-HT stimulation (n = 5 each). *, P < 0.05 compared with controls. The ex-
periment was performed in two independent series. Error bars indicate SE.JEM VOL. 208, May 9, 2011 
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However, expression of 5-HT2B was strongly increased in   
fibrotic tissue compared with unaffected tissue from healthy 
controls (Fig. 3 A). Double staining for the fibroblast-specific 
marker  prolyl-4-hydroxylase    and  5-HT2B  demonstrated 
that almost all fibroblasts stained positive for 5-HT2B in fi-
brotic tissue but not in controls (Fig. S2 E). Of note, intensive 
staining for 5-HT2B was observed in -SMA ( smooth 
muscle actin)–positive, SM22- (smooth muscle protein 
22 )–negative myofibroblasts in skin of SSc patients (Fig. 3 B). 
Together with a previous report of an increased serum con-
centration of 5-HT in SSc (Biondi et al., 1988), these findings 
suggest that the 5-HT/5-HT2B axis is up-regulated in sys-
temic fibrotic disease.
5-HT2B activates TGF-/Smad signaling
TGF- has been identified as a key player in the pathogenesis 
of fibrosis (Varga and Abraham, 2007). When we compared 
the effects of 5-HT and TGF- in col 1a2 reporter assays, we 
observed different time kinetics. The stimulatory effects of 5-HT 
peaked after 24 h, whereas the maximal effects of TGF- 
were observed after 6 h (Fig. S1 D). The delayed activation by   
5-HT implicates that the profibrotic effects of 5-HT might be 
mediated indirectly by induction of a second messenger.
To investigate whether TGF- itself might be this second 
mediator, we first analyzed the effects of 5-HT on the expression 
of TGF-1 and of its target gene PAI-1 (plasminogen activator 
inhibitor 1). 5-HT dose-dependently increased the mRNA   
levels of TGF-1 and PAI-1 in SSc fibroblasts (Fig. 4, A and B). 
Furthermore, 5-HT induced a time-dependent increase in nu-
clear levels of phospho-Smad3, the typical intracellular mediator 
of TGF- signaling (Fig. 4 C). We next evaluated whether the 
profibrotic effects of 5-HT depend on TGF-. Preincubation of 
annexin V–  or  propidium  iodide–positive  fibroblasts  were 
observed upon incubation with terguride or SB 204741, dem-
onstrating that the reduced synthesis of extracellular matrix 
proteins upon inhibition of 5-HT2B is not caused by toxicity 
of the inhibitors (unpublished data).
As off-target effects of the chemical inhibitors cannot be 
fully excluded, SSc fibroblasts were transfected with small 
interfering RNAs (siRNAs) against 5-HT2B, which efficiently 
reduced mRNA and protein levels of 5-HT2B (Fig. 2 E). 
Moreover, silencing of 5-HT2B in the presence of 5-HT sig-
nificantly decreased mRNA expression for col 1a1, col 1a2, 
and fibronectin-1 compared with SSc fibroblasts transfected 
with nontargeting control siRNA (Fig. 2, F–H), suggesting 
that 5-HT2B plays a crucial role for the synthesis of extracel-
lular matrix proteins in dermal fibroblasts.
To exclude the possibility that the decreased synthesis of 
extracellular matrix proteins is counter-regulated by induc-
tion of matrix-degrading enzymes or their inhibitors, the ex-
pression of MMPs (matrix metalloproteinases) and TIMPs 
(tissue inhibitors of MMPs) was analyzed in fibroblasts treated 
with 5-HT, terguride, and SB 204741 and in fibroblasts 
transfected with 5-HT2B siRNA. The expression of MMP-
1, MMP-2, MMP-3, and MMP-13 and TIMP-1, TIMP-2, 
TIMP-3, and TIMP-4 was not affected upon stimulation with 
5-HT or inhibition of 5-HT2B (unpublished data).
5-HT2B is overexpressed in skin of SSc patients
After demonstrating that 5-HT exerts its profibrotic effects 
via 5-HT2B, we were interested whether 5-HT2B might be 
up-regulated in human fibrotic diseases. 5-HT2B was detect-
able by immunohistochemistry in the fibrotic skin of SSc pa-
tients as well as in normal skin of healthy individuals (Fig. 3). 
Figure 2.  Inhibition of 5-HT2B but not of 5-HT1B or 5-HT2A reduces the 5-HT–induced expression of extracellular matrix proteins.  
(A–D) Inhibition of 5-HT receptors by selective inhibitors at concentrations of 0.1 and 1.0 µM. mRNA levels of col 1a1 (A), col 1a2 (B), and fibronectin-1  
(C) and release of collagen protein (D) after incubation with the 5-HT1B antagonist SB 224289, ketanserin (5-HT2A), and the 5-HT2B inhibitor SB 204741  
(n = 7 each, two independent series). *, P < 0.05 compared with 5-HT–stimulated cells. (E–H) Knockdown of 5-HT2B by siRNA. (E) Expression levels of  
5-HT2B protein after nucleofection with 5-HT2B and mock siRNA. (F–H) mRNA levels of col 1a1 (F), col 1a2 (G), and fibronectin-1 (H) after knockdown of  
5-HT2B by siRNA in 5-HT–stimulated SSc dermal fibroblasts compared with mock-transfected cells (n = 5, two independent series). Error bars indicate SE.964 Serotonin in 5-HT2B fibrotic disease | Dees et al.
The mRNA levels of col 1a1, col 1a2, and fibronectin-1 were 
only slightly reduced by neutralizing antibodies against TGF-1 
in unstimulated fibroblasts, suggesting that the observed effects 
of anti–TGF-1 antibodies in 5-HT–
stimulated fibroblasts were caused by 
blockade of the stimulatory effects of   
5-HT rather than caused by effects on 
the basal synthesis (Fig. 4, D–F). Similar 
results were also obtained for healthy 
dermal fibroblasts (unpublished data).
SSc  fibroblasts  with  neutralizing  antibodies  against TGF-1 
completely abrogated the profibrotic effects of 5-HT on mRNA 
expression of col 1a1, col 1a2, and fibronectin-1 (Fig. 4, D–F). 
Figure 3.  5-HT2B is overexpressed in patients with SSc. (A) 5-HT2B was detectable by immunohistochemistry in fibroblasts, keratinocytes, and mi-
crovessels of SSc patients and controls. Two representative tissue sections and an isotype control are shown. (B) 5-HT2B expression in SM22-–negative 
and -SMA–positive myofibroblasts. A representative skin section of an SSc patient is shown. SM22- as specific marker for vascular smooth muscle 
cells was stained with DAB, the myofibroblast marker -SMA with Alexa Flour 594 (red), and 5-HT2B with Alexa Flour 488 (green; n = 8 each). The stain-
ings were performed in three independent series. Bars: (A and B [top]) 50 µm; (B, bottom) 10 µm.
Figure 4.  5-HT exerts its profibrotic 
effects via activation of TGF-/Smad-
dependent pathways. (A and B) mRNA levels 
of TGF-1 (A) and PAI-1 (B) in 5-HT–stimu-
lated SSc fibroblasts (n = 9, three independent 
series). (C) Nuclear accumulation of p-Smad3 
protein complexes after 12 and 24 h of stimu-
lation with 1 µM 5-HT (n = 3). (D–F) mRNA 
expression of col 1a1 (D), col 1a2 (E), and 
fibronectin-1 (F) upon incubation with 500 
ng/ml of neutralizing antibodies (Ab) against 
TGF-1 in 5-HT–stimulated SSc fibroblasts  
(n = 5 each, two independent series). *, P < 0.05 
compared with 5-HT–stimulated (D–F) or 
nonstimulated (A and B) controls. Error bars 
indicate SE.JEM VOL. 208, May 9, 2011 
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The antifibrotic effects of the inhibition of 5-HT2 were 
further tested in a therapeutic approach in a modified bleo-
mycin model. When the treatment with terguride was started 
after induction of fibrosis, terguride did not only prevent fur-
ther progression, but induced regression of fibrosis (Fig. S3 B). 
Dermal thickening decreased by 78 ± 4% in mice treated with 
terguride for the last 3 wk compared with mice challenged 
with bleomycin for 6 wk (P = 0.003) and by 66 ± 4% compared 
with mice injected with bleomycin for 3 wk (P = 0.002;   
Fig. S3 C). The collagen content and the number of myofi-
broblasts were also efficiently reduced (Fig. S3, D and E).
To confirm the role of 5-HT2B in experimental fibrosis   
by a genetic approach, we evaluated the effects of bleomycin in 
mice lacking 5-HT2B. No histological changes or differences 
in dermal thickness were observed in untreated 5-HT2B
/ 
mice (Fig. 6 A). However, 5-HT2B
/ mice were almost com-
pletely protected from bleomycin-induced fibrosis. Bleomycin 
Targeting of 5-HT2B exerts potent antifibrotic effects
We then assessed different inhibitors of 5-HT receptor for 
their antifibrotic activity in the mouse model of bleomycin-
induced dermal fibrosis. Imatinib, a tyrosine kinase inhibitor 
with well established antifibrotic effects in this model, served 
as positive control (Wang et al., 2005; Distler et al., 2007a). No 
signs of toxicity were observed upon treatment with tergu-
ride, cyproheptadine, SB 204741, and imatinib. Injection of 
bleomycin potently stimulated the expression of 5-HT2B and 
induced dermal fibrosis (Fig. 5 A and Fig. S3 A). However, the 
5-HT2 inhibitors terguride and cyproheptadine as well as the 
selective 5-HT2B inhibitor SB 204741 (Goldberg et al., 1979; 
Bonhaus et al., 1995; Glusa and Pertz, 2000; Jähnichen et al., 
2005) efficiently prevented bleomycin-induced dermal thick-
ening (Fig. 5, A and B). Collagen content and myofibroblast 
counts were also dose-dependently reduced by the inhibition 
of 5-HT2B (Fig. 5, C and D).
Figure 5.  Inhibition of 5-HT signaling by the 5-HT2 inhibitors terguride, cyproheptadine, and SB 204741 prevents accumulation of extra-
cellular matrix in experimental dermal fibrosis. (A) Representative trichrome-stained tissue sections are shown: control mice injected intracutane-
ously with NaCl (n = 10), bleomycin-challenged mice without antifibrotic treatment (n = 10), mice receiving bleomycin and terguride at a concentration 
of 0.2 mg/kg/bid (n = 8), mice treated with bleomycin and terguride at a concentration of 0.6 mg/kg/bid (n = 8), mice treated with bleomycin and cypro-
heptadine at a concentration of 10 mg/kg/d (n = 6), mice treated with bleomycin and SB 204741 at a concentration of 5 mg/kg/d (n = 6), and mice 
treated with bleomycin and imatinib at a concentration of 50 mg/kg/d (n = 6). Bars, 100 µm. (B) Dermal thickening upon challenge with bleomycin and 
treatment with terguride, cyproheptadine, SB 204741, or imatinib. (C) Collagen accumulation in lesional skin as analyzed with the SirCol collagen assay. 
(D) Myofibroblast counts after treatment of bleomycin-challenged mice with terguride, cyproheptadine, SB 204741, or imatinib. *, P < 0.05 compared with 
bleomycin-treated mice without antifibrotic treatment. The experiment was performed in two independent series. Error bars indicate SE.966 Serotonin in 5-HT2B fibrotic disease | Dees et al.
in 5-HT2B
//Tsk-1 mice compared with 5-HT2B
+/+/Tsk-1 
mice (Fig. 7, A and B). Furthermore, the collagen content and 
the myofibroblast numbers in the skin of 5-HT2B
//Tsk-1 
mice were significantly decreased compared with 5-HT2B
+/+/
Tsk-1 mice (Fig. 7, C and D).
Inhibition of platelet activation ameliorates bleomycin-
induced skin fibrosis and the Tsk-1 phenotype
To confirm the link between increased platelet activation and 
increased 5-HT/5-HT2B signaling, we first measured the levels 
of 5-HT in fibrotic skin. The concentration of 5-HT in lesional 
skin increased to 5.8 ± 0.5 ng/mg in bleomycin-injected mice 
compared with 3.2 ± 0.2 ng/mg in control mice (P = 0.02).   
In the Tsk-1 model, the concentration of 5-HT was increased 
from 4.0 ± 0.4 ng/mg to 6.7 ± 1.0 ng/mg (P = 0.04). Thus, 
levels of 5-HT are up-regulated in different models of experi-
mental fibrosis in accordance with the increased levels seen in 
human SSc (Stachów et al., 1979; Biondi et al., 1988).
Because the vast majority of 5-HT in nonneuronal tissues 
is derived from platelets, we hypothesized that inhibition of 
platelet activation might reduce the tissue levels of 5-HT and 
prevent experimental fibrosis. Indeed, treatment with the P2Y12 
receptor inhibitor clopidogrel reduced the 5-HT content in 
the fibrotic skin of bleomycin-challenged mice by 58 ± 21% 
(P = 0.03). In parallel, clopidogrel decreased dermal thickening 
by 61 ± 13% compared with control mice (P = 0.001; Fig. S5,  
A and B). Consistently, the collagen content and the myofibro-
blast counts were significantly reduced (Fig. S5, C and D).
Hypodermal thickening in Tsk-1 mice was also reduced 
by 51 ± 16% (P = 0.009) upon treatment with clopidogrel 
(Fig. S5, E and F). Additionally, the collagen content and the 
number of activated myofibroblasts in skin were significantly 
decreased (Fig. S5, G and H).
Lack of 5-HT in platelets via knockout of TPH1 prevents 
experimental dermal fibrosis
Platelet granules do not only contain 5-HT but also other 
growth factors. To demonstrate that 5-HT is the major profi-
brotic mediator released by platelets, we investigated the out-
come of TPH1-deficient (TPH1/) mice in experimental 
fibrosis. TPH1/ mice do not completely lack 5-HT, but   
total blood levels of 5-HT are reduced to 5% as compared 
with wild-type animals (Walther et al., 2003b). Consistent 
with an important role of platelet-derived 5-HT in fibrosis, 
the profibrotic effects of bleomycin were markedly reduced in 
TPH1/ mice (Fig. 8 A). Dermal thickening was decreased by 
61 ± 6% (P = 0.004), and the collagen content as well as 
myofibroblast counts were significantly reduced in TPH1/ 
mice as compared with TPH1+/+ mice (Fig. 8, B–D).
TPH1/ mice were interbred with Tsk-1 mice to yield 
Tsk-1 mice lacking 5-HT in platelets. Fibrosis was also effi-
ciently ameliorated in TPH1//Tsk-1 with reduced hypo-
dermal  thickening,  decreased  hydroxyproline  content,  and 
lower myofibroblast counts mice as compared with TPH1+/+/
Tsk-1 (Fig. S6, A–D).
induced only minor dermal thickening, and the hydroxypro-
line content and the myofibroblast numbers did not increase in 
5-HT2B
/ mice upon bleomycin challenge (Fig. 6, A–C).
To assess the role of 5-HT2B in a less inflammation- 
dependent model of fibrosis, the Tsk-1 (tight skin 1) model was 
used. The Tsk-1 model is characterized by increased hypoder-
mal thickness compared with matched wild-type mice because 
of a tandem duplication in the fibrillin-1 gene (Green et al., 
1976). Consistent with the findings in human SSc and in bleo-
mycin-induced fibrosis, 5-HT2B was overexpressed in skin sec-
tions of Tsk-1 mice (Fig. S4 A). Treatment with the 5-HT2B 
inhibitor SB 204741 normalized fibrotic changes observed in 
Tsk-1 mice (Fig. S4 B). Hypodermal thickening, collagen con-
tent, and the differentiation of resting fibroblasts into myofi-
broblasts in Tsk-1 mice were significantly reduced upon 
treatment with SB 204741 (Fig. S4, C–E).
Moreover, when 5-HT2B
/ mice were crossed with 
Tsk-1 mice, hypodermal thickening was significantly reduced 
Figure 6.  Mice lacking 5-HT2B are protected from bleomycin- 
induced dermal fibrosis. (A) Trichrome-stained tissue sections of  
5-HT2B
/ and wild-type mice. Representative tissue sections are shown: 
5-HT2B
+/+ mice injected with NaCl intracutaneously, 5-HT2B
/ mice re-
ceiving intracutaneous injections of NaCl, 5-HT2B
+/+ mice receiving intra-
cutaneous injections of bleomycin, and 5-HT2B
/ mice injected with 
bleomycin (n = 8 each). Bars, 100 µm. (B) Dermal thickening in bleomycin-
challenged 5-HT2B
/ and wild-type mice. (C) Myofibroblast number in  
5-HT2B–deficient and wild-type mice upon bleomycin challenge. *, P < 0.05 
compared with bleomycin-injected wild-type mice. The experiment was 
performed in two independent series. Error bars indicate SE.JEM VOL. 208, May 9, 2011 
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and vascular endothelial growth factor, which are increased in 
the serum of SSc patients (Soma et al., 1993; Mercié et al., 
1995; Distler et al., 2002). Platelets are also the largest storage 
pool for 5-HT, and elevated plasma levels of 5-HT have   
been observed in systemic fibrosis (Biondi et al., 1988). Thus,   
microangiopathy with subsequent platelet activation and in-
creased release of 5-HT might further activate 5-HT/5-HT2B 
signaling in addition to the 5-HT2B overexpression in fibrotic 
diseases. Indeed, inhibition of platelet activation or selective 
inhibition of the synthesis of 5-HT prevents experimental fi-
brosis in different mouse models, thereby highlighting the 
role of platelet activation in fibrosis.
Our study could also explain the molecular mechanism of 
the clinical association between carcinoid tumors and fibrosis. 
Carcinoid  tumors  are  neuroendocrine  tumors  producing 
large amounts of 5-HT. Tissue fibrosis is often found in pa-
tients with carcinoid tumors, both locally and systemically 
(Modlin et al., 2004). Local tissue fibrosis in the peritumoral 
tissue is found in most patients. The accumulation of extra-
cellular matrix might be substantial and by far exceed the ac-
tual  tumor  volume  (Moertel  et  al.,  1961;  Makridis  et  al., 
1996). The most common systemic fibrotic manifestation is 
carcinoid heart disease with fibrotic changes of the cardiac 
DISCUSSION
Herein, we demonstrate that 5-HT2B signaling plays a central 
role for fibrosis. Several experimental levels such as 5-HT2B–
null mice and treatment with small molecule inhibitors as 
well as in vitro and ex vivo studies in humans suggested that 
binding of 5-HT to its receptor 5-HT2B is a key step in tissue 
fibrosis. We believe that these findings have direct clinical im-
plications: potent inhibitors of 5-HT2 receptors, including 
cyproheptadine and terguride used in our study as well as mi-
anserin and lisuride, are already in clinical use and are well 
tolerated (Obeso et al., 1986; von Werner et al., 1989; Moertel 
et al., 1991; Szegedi and Schwertfeger, 2005). Furthermore, 
selective inhibitors of 5-HT2B are in clinical development and 
might be available in the near future. Thus, inhibition of 5-HT2B 
might be a promising novel therapeutic approach as efficient 
antifibrotic therapies are not yet available.
Patients affected with SSc develop a characteristic micro-
angiopathy as the result of ongoing endothelial cell damage 
and endothelial cell activation early in the course of the dis-
ease, before tissue fibrosis becomes evident (Sgonc et al., 1996; 
Varga and Abraham, 2007). Loss of the anticoagulant properties 
of the endothelial cell layer results in platelet activation and 
the release of bioactive molecules such as -thrombomodulin 
Figure 7.  Deficiency of 5-HT2B corrects the histological changes in Tsk-1 mice. (A) Representative sections of trichrome staining are shown:  
5-HT2B
+/+ mice without Tsk-1 allele (n = 5), 5-HT2B
/ mice without Tsk-1 allele (n = 8), 5-HT2B
+/+/Tsk-1 mice (n = 5), and 5-HT2B
//Tsk-1 mice (n = 8). 
Vertical bars indicate the hypodermal thickness. Bars, 250 µm. (B) Hypodermal thickness in 5-HT2B–deficient Tsk-1 mice. (C) Collagen content in the skin  
of 5-HT2B
//Tsk-1 mice. (D) Myofibroblast counts in Tsk-1 mice after knockdown of 5-HT2B. *, P < 0.05 compared with 5-HT2B
+/+/Tsk-1 mice. The measure-
ments were performed twice. Error bars indicate SE.968 Serotonin in 5-HT2B fibrotic disease | Dees et al.
has been implicated in the development of fibrotic changes 
by selected ergots such as pergolide or bromocriptine, an-
orexins like fenfluramine, or drugs of abuse as for example 
MDMA (3,4-methylenedioxymethamphetamine; also known 
as ecstasy; Rothman et al., 2000; Setola et al., 2003; Hofmann 
et al., 2006; Roth, 2007). As we demonstrate herein that acti-
vation of 5-HT2B potently stimulates the production of extra-
cellular matrix proteins, it might be concluded that activation 
of 5-HT2B by the metabolite methylergonovine might be suf-
ficient to promote the development of fibrosis. The impor-
tance of 5-HT signaling for fibrotic diseases is supported by 
recent studies with 5-HT receptor antagonists in experimen-
tal pulmonary or liver fibrosis (Ruddell et al., 2006; Fabre 
et al., 2008). Thus, our findings might have widespread impli-
cations, namely that inhibition of the 5-HT2B pathway might 
be a promising strategy for fibrotic disorders.
MATERIALS AND METHODS
Patients, mice, and fibroblast cultures. Fibroblast cultures were ob-
tained from skin biopsies of SSc patients and healthy volunteers as de-
scribed previously (Akhmetshina et al., 2008). All patients fulfilled the 
criteria for SSc as suggested by LeRoy and Medsger (2001). Patient char-
acteristics are summarized in Table S1. All patients and controls signed a 
valves (Hallen, 1964). The lesions are located on the mural 
and valvular endocardium and consist of a matrix-rich stroma 
and interspersed myofibroblasts, which were also found in an 
animal model of carcinoid tumors (Gustafsson et al., 2005). 
Pleural, pulmonary, gastrointestinal, retroperitoneal, and skin 
fibrosis can occur. Skin involvement manifests as scleroderma-
like disease with dermal fibrosis (Zarafonetis et al., 1958; Fries   
et al., 1973; Modlin et al., 2004). Of note, dermal fibrosis has 
been reported to regress after effective treatment of carcinoid 
tumors (Pavlovic et al., 1995). Despite these abundant studies, 
the molecular mechanism by which these tumors caused 
tissue fibrosis was unclear. Some authors suggested that tissue 
hypoxia caused by vasospasm or compression might trigger 
fibrosis (Modlin et al., 2004). Others speculated that tachykinins 
released from carcinoid tumors might mediate tissue fibrosis 
(Katayama and Nishioka, 1997; Ashour et al., 2006). Others 
proposed that 5-HT might be the cause of carcinoid-associated 
fibrosis (MacDonald et al., 1958; Hallen, 1964).
The ergot methysergide can also cause retroperitoneal fi-
brosis. The metabolism of the 5-HT2B antagonist methyser-
gide to its active metabolite methylergonovine, which is a 
potent 5-HT2B agonist, provides an explanation for this paradox-
ical observation (Reimund, 1987). Similarly, 5-HT2B agonism 
Figure 8.  Mice lacking TPH1 are protected from bleomycin-induced dermal fibrosis. (A) Trichrome-stained tissue sections are shown: TPH1+/+ 
mice injected with NaCl intracutaneously (n = 7), TPH1/ mice with intracutaneous injections of NaCl (n = 5), bleomycin-injected TPH1+/+ mice (n = 7), 
and TPH1/ mice challenged with bleomycin (n = 5). Bars, 100 µm. (B) Dermal thickness in bleomycin-challenged TPH1-deficient mice. (C) Collagen pro-
tein content in bleomycin-challenged TPH1/ mice as analyzed by hydroxyproline assay. (D) Changes in the number of -SMA–positive myofibroblasts 
upon bleomycin challenge in TPH1-deficient mice. *, P < 0.05 compared with bleomycin-injected wild-type mice. The experiment was performed in two 
independent series. Error bars indicate SE.JEM VOL. 208, May 9, 2011 
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Collagen measurements. Total soluble collagen in cell culture superna-
tants was quantified using the SirCol collagen assay (Biocolor; Akhmetshina 
et al., 2008). To detect also highly cross-linked collagen, the collagen content 
in skin samples was analyzed by determination of the hydroxyproline content 
(Woessner, 1961).
Western blot. Nuclear and cytoplasmic extracts were prepared as previously 
described (Andrews and Faller, 1991; Khelifi et al., 2005). Polyvinylidene   
fluoride membranes were incubated with polyclonal rabbit anti–5-HT2B 
(GeneTex) or monoclonal rabbit anti–phospho-Smad3 antibodies (Cell Sig-
naling Technology). Equal loading of proteins was confirmed by visualization 
of the nuclear protein lamin A/C (Cell Signaling Technology) and the cyto-
plasmic protein -actin (Sigma-Aldrich). Quantification was performed with 
ImageJ software (version 1.41; National Institutes of Health).
Immunohistochemistry for 5-HT2B, -SMA, and SM22-. Skin sec-
tions from SSc patients and controls were stained with polyclonal rabbit anti–
5-HT2B antibodies. A subset of 5-HT2B–stained sections was double stained 
with the fibroblast marker prolyl-4-hydroxylase  (Acris Antibodies). To ana-
lyze the expression of 5-HT2B in myofibroblasts, we performed triple staining 
for 5-HT2B, the myofibroblast marker -SMA (clone 1A4; Sigma-Aldrich), 
and SM22- (Abcam) as specific marker for vascular smooth muscle cells 
to distinguish myofibroblasts from vessels. Antibodies labeled with horse-
radish peroxidase (Dako), alkaline phosphatase (Jackson ImmunoResearch 
Laboratories, Inc.), and Alexa Flour 488 or Alexa Flour 594 (both Invitrogen) 
were used as secondary antibodies. The expression of SM22- and 5-HT2B 
in single- and double-stained sections was visualized with DAB (diamino-
benzidine) peroxidase substrate solution (Sigma-Aldrich), and the expression 
of prolyl-4-hydroxylase  with BCIP/NBT (5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium; Vector Laboratories). Isotype antibodies in 
the same concentration were used for controls. Myofibroblasts in mouse sec-
tions were identified by staining for -SMA as described previously (Distler 
et al., 2007a).
MTT assay. The metabolic activity of dermal fibroblasts incubated with inhib-
itors of 5-HT2B was measured using the MTT (3, [4, 5-dimethylthiazol-2-yl]   
2, 5-diphenyl-tetrazolium bromide) method (Distler et al., 2005). In brief, SSc 
and healthy dermal fibroblasts were incubated with terguride or SB 204741 in 
concentrations of 0.1 and 1.0 µM in 96-well plates for 20 h. After removing 
100 µl of the medium, MTT was added at a final concentration of 1 mg/ml, and 
the cells were incubated at 37°C for 4 h. After dilution with 300 µl of 0.04 N 
HCl in isopropanol, the cells were analyzed using the ELISA reader (Spectra 
MAX 190 microplate spectrophotometer; Molecular Devices) at a test wave-
length of 570 nm with a control wavelength of 630 nm. Untreated fibroblasts 
were used as negative controls, and all other results were normalized to untreated 
cells. Fibroblasts incubated with 50% DMSO served as positive controls.
Quantification of apoptotic and necrotic cells. Dermal fibroblasts were 
incubated with terguride or SB 204741 for 7 d. The number of apoptotic and 
necrotic cells was analyzed as described previously (Distler et al., 2007a).
Bleomycin-induced dermal fibrosis. Skin fibrosis was induced in 6-wk-
old, pathogen-free, female DBA/2 mice (Charles River) by local injections of 
bleomycin for 21 d. Seven groups received subcutaneous injections of 100 µl 
bleomycin dissolved in 0.9% NaCl at a concentration of 0.5 mg/ml in de-
fined areas of the upper back every other day to induce dermal fibrosis. Six 
groups of bleomycin-challenged mice were treated with the P2Y12 receptor 
inhibitor clopidogrel (25 mg/kg/d) by oral gavage, terguride (0.2 mg/kg/bid 
and 0.6 mg/kg/bid) by intraperitoneal injections, cyproheptadine (10 mg/
kg/d) by oral gavage, SB 204741 (5 mg/kg/d) subcutaneously, or imatinib 
(50 mg/kg/d) by intraperitoneal injections, which served as positive control. 
One group with subcutaneous injections of 100 µl of 0.9% NaCl served as 
control group. After 21 d, animals were sacrificed by cervical dislocation.
The mouse model of bleomycin-induced dermal fibrosis was also used 
to evaluate a potential protection from fibrosis in mice lacking TPH1 or 5-HT2B. 
Four groups of mice were analyzed. Two groups consisted of TPH1-deficient 
consent  form  approved  by  the  local  institutional  review  boards.  All   
human protocols were approved by the ethical board of the University of 
Erlangen-Nuremberg.
TPH1/ mice and 5-HT2B
/ mice have been described previously 
(Nebigil et al., 2000; Walther et al., 2003b). All mouse experiments were ap-
proved by the Government of Mittelfranken.
ELISA. 4-mg skin biopsies of the injected area were analyzed by competi-
tive ELISA for 5-HT using a serotonin ELISA kit (GenWay).
Stimulation with 5-HT and 5-HT receptor inhibition. For stimulation 
experiments, a special FCS depleted of 5-HT was used (HyClone). Dermal 
fibroblasts were stimulated with 5-HT (Sigma-Aldrich) in concentrations 
from 0.01 to 1.0 µM.
Cells were incubated with the nonselective 5-HT2 inhibitor terguride 
(0.01–1.0 µM) or the selective inhibitors SB 224289 (5-HT1B), ketanserin 
(5-HT2A), and SB 204741 (5-HT2B) at concentrations of 0.1 and 1.0 µM 
(Kasho et al., 1998; Lawrie et al., 2005). The Ki values of all chemical inhibi-
tors according to the National Institute of Mental Health Ki Database are 
given in Table S2. 5-HT was added 1 h after the inhibitors at a concentration 
of 1.0 µM.
Transfection with siRNAs against 5-HT2B. SSc fibroblasts were trans-
fected  with  1.5  µg  siRNA  duplexes  against  5-HT2B  using  the  human 
dermal  fibroblast  Nucleofector  kit  (Lonza;  Jüngel  et  al.,  2007). Two  dif-
ferent siRNA duplexes with the following sequences were used: siRNA   
duplex 1 sense, 5-CCGCAUCCAUCAUGCAUCU-3; and antisense, 
5-AGAUGCAUGAUGGAUGCGG-3; and siRNA duplex 2 sense, 5-GUG-
GUGUGGUUAAUUUCAA-3; and antisense, 5-UUGAAAUUAAC-
CACACCAC-3. Fibroblasts transfected with nontargeting control siRNAs 
(Invitrogen) were used as controls. Medium was changed after 6 h to remove 
the Nucleofector solution. Cells were harvested after 48 h.
Selective  inhibition  of TGF-  signaling. Fibroblasts were stimulated 
with 1 µM 5-HT in the presence of neutralizing mouse anti–human TGF-1 
or IgG control antibodies (R&D Systems) at a concentration of 500 ng/ml 
as described previously (Distler et al., 2007b).
mRNA stability assay. The mRNA stability assay was performed to inves-
tigate whether 5-HT stabilizes collagen or fibronectin mRNA as described 
previously (Distler et al., 2004). SSc fibroblasts were stimulated with 1 µM   
5-HT. Actinomycin D was added at a concentration of 10 µg/ml 6 h later. 
Nonstimulated fibroblasts with and without actinomycin D served as con-
trols. Fibroblasts were harvested 4, 8, 12, 18, and 24 h after the addition of ac-
tinomycin D and analyzed with real-time PCR.
Luciferase reporter assay. The -353 COL1A2/LUC construct was pro-
vided by M. Trojanowska (Boston University School of Medicine, Boston, 
MA; Czuwara-Ladykowska et al., 2001). HEK293T cells were transfected in 
serum-free medium with 0.5 µg of reporter construct mixed with polyethyl-
enimine. A common lacZ reporter vector was used as control. Cells were 
stimulated with 5-HT or TGF- directly after transfection.
Quantitative real-time PCR. Gene expression was quantified by TaqMan 
or by SYBR Green real-time PCR (ABI Prism 7300 sequence detection 
system; Applied  Biosystems)  as  described  previously  (Akhmetshina  et  al., 
2008). Total RNA was isolated with the NucleoSpin RNA II extraction   
system (Macherey-Nagel) according to the instructions of the manufacturer. 
RT into cDNA was performed as described previously (Akhmetshina et al., 
2008) using random hexamers. Samples without enzyme in the RT reaction 
(non-RT controls) were used as negative controls. Unspecific signals caused by 
primer dimers were excluded by dissociation curve analysis and samples without 
cDNA (no template controls). A predeveloped 18S assay (Applied Biosys-
tems) was used to normalize for the amounts of loaded cDNA. Differences 
were calculated with the comparative Ct method for relative quantification.970 Serotonin in 5-HT2B fibrotic disease | Dees et al.
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